Anavex Life Sciences (AVXL) Convertible Debt (2014)
Anavex Life Sciences recorded quarterly Convertible Debt of $1091.0 in Q2 2014, up 7.91% quarter-over-quarter from $1011.0 in Q1 2014.
Anavex Life Sciences' Convertible Debt history runs 1 years deep, the most recent figure standing at $1091.0 for Q2 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | 1,091.00 |
| Mar 31, 2014 | 1,011.00 |